By Anne Sutton, ASCO Marketing and Communications

ASCO is thrilled to be returning to Asia, bringing ASCO Breakthrough to Yokohama, Japan, on August 3-5, 2023. The meeting is cohosted by ASCO, the Japan Society of Clinical Oncology (JSCO), and the Japanese Society of Medical Oncology (JSMO), and supported by many other regional collaborators. Join us for this one-of-a-kind meeting that explores cutting-edge advances in cancer care technology and innovations that can help transform care for people living with cancer.

For attendees not able to join us in person in 2023, ASCO Breakthrough offers a robust online experience including livestream sessions, live question-and-answer, audience polling, and more. If you’re curious about this new meeting from ASCO, it’s not too late to register to attend online or watch on demand this year. Then, plan ahead to attend the next ASCO Breakthrough in person: 2024 dates will be announced soon so you can reserve time in your schedule to travel to next year’s meeting and beyond.

You won’t want to miss three days of interactive sessions and presentations by key opinion experts focusing on the latest research results and clinical applications in specific disease sites. World-renowned leaders Hiroshi Mikitani, of Rakuten, Inc., and Maryellen L. Giger, PhD, of the University of Chicago, will open the meeting with a timely and impactful keynote. Additionally, there will be a special session addressing challenges and potential solutions in cancer care delivery in low- and middle-income countries, led by Gilberto Lopes, MD, MBA, FASCO, of Sylvester Comprehensive Cancer Center and the University of Miami.

In addition to these keynotes and special sessions, ASCO Breakthrough features a broad spectrum of topics ranging from novel therapeutics—including CAR T and adoptive cell therapies, CRISPR and gene editing, drugging the undruggable targets, and microbiome modulation—to using artificial intelligence and next-generation multiomics. There will also be a session on international cancer networks to examine the globalization of oncologic research across geographic boundaries and disease disciplines through existing and future academic and pharmaceutical alliances. Additionally, over 150 abstracts will be presented across two all-day Poster Sessions, offering opportunities for networking and research collaboration.

To register, visit breakthrough.asco.org.

A Sneak Peek at What’s Happening Onsite at ASCO Breakthrough

There are a host of onsite opportunities to help attendees make connections, including a Meet the Experts Networking Luncheon, two Networking Receptions, a Connect 1:1 with Expert ASCO Breakthrough Faculty Luncheon, and a Women’s Networking Reception.

Attendees are also invited to personally connect and engage with key oncology leaders during meet-and-greets scheduled for the morning and afternoon breaks on Thursday and Friday. You will have the unique opportunity to speak with ASCO, JSCO, and JSMO leadership, including ASCO CEO Clifford A. Hudis, MD, FACP, FASCO, 2023-2024 ASCO president Lynn M. Schuchter, MD, FASCO, Conquer Cancer Board chair Howard A. Burris III, MD, FACP, FASCO, ASCO past president Bruce E. Johnson, MD, FASCO, JSMO Board member and JSCO vice chair Takayuki Yoshino, MD, PhD, and JSCO chair Yuichiro Doki, MD, PhD. No sign up or reservation is required.

Follow ASCO Breakthrough on Social Media

Connect with ASCO on social media to keep up with the latest information from the 2023 ASCO Breakthrough meeting. Follow along on Twitter, Instagram, and LinkedIn/Facebook, and share your own meeting experience using the official hashtag #ASCOBT23.

New for 2023, ASCO Breakthrough abstract presenters, featured speakers, and attendees are encouraged to use the social media toolkit to access social media resources, content, and tips to promote your participation at the meeting.

What Leaders Are Saying About ASCO Breakthrough 2023

“This meeting is important for research dissemination because we are expecting abstracts from completely different aspects of cancer care and research, like drug development, experimental therapeutics, patient access, practice, and more. For individuals attending this meeting for the first time, I hope it is in person! Please come with an open mind. I think you’re to discover a variety of topics which will inspire you, broaden your areas of interest, and make your cancer care research more impactful.”

—Lillian L. Siu, MD, FRCPC, FASCO, 2023 ASCO Breakthrough Program Committee chair

“ASCO Breakthrough stands out as an innovative platform that illuminates emerging discoveries and technologies in cancer care going beyond traditional oncology. The meeting showcases cutting-edge areas such as artificial intelligence, multiomics technology, gene editing, and CAR-T technology, providing a glimpse into the future of cancer care. [The meeting] brings together through leaders to inspire collaboration and seek solutions [and] provides an ideal opportunity for researchers to disseminate their findings, exchange ideas, and establish connection with peers from around the world.”

—Tetsuya Mitsudomi, MD, PhD, 2023 ASCO Breakthrough Advisory Committee chair

“ASCO Breakthrough is unlike any other oncology meeting. It brings together a more diverse audience and strives to foster a more relaxed experience that is conducive to understanding not only the here and now, but also where we are likely to be in [the near future]. Come for the feedback, networking, and professional growth that an in-person ASCO experience provides.”

—Peter Yu, MD, FASCO, 2023 ASCO Breakthrough Co-Host Committee chair

“At ASCO Breakthrough, I am excited to have the chance to interactively discuss amongst the oncology thought leaders of Japan and beyond about innovative ideas that will take cancer care to the next level. I am confident this will be a prominent meeting for research dissemination.”

—Takayuki Yoshino, MD, PhD, 2023 ASCO Breakthrough Co-Host Committee member

“At the ASCO Breakthrough Manuscript Development Workshop, mentors will directly teach the research presenters how to improve their abstract for publication. In Japan, this is a one-of-a-kind opportunity for young cancer researchers. I want to say to young oncologists, don’t miss this chance.”

—Yuichiro Doki, MD, PhD, JSCO chair and 2023 ASCO Breakthrough Co-Host Committee member

ASCO Breakthrough is endorsed by the Japan Ministry of Health, Labor, and Welfare.